Peer-Reviewed Study Shows Telomir-Zn Cuts Zebrafish HOMA-IR from 12 to 3
TELO•Telomir Pharmaceuticals published a peer-reviewed preclinical study showing Telomir-Zn normalized fasting blood glucose and reduced HOMA-IR from 10–12 to 3 in a diet-induced zebrafish Type 2 diabetes model after 14 days. Results validate its metal-homeostasis mechanism and underpin its FDA-cleared IND for Phase 1/2 triple-negative breast cancer trials.
1. Preclinical Study Outcomes
Telomir Pharmaceuticals’ peer-reviewed study reported that a 14-day regimen of Telomir-Zn normalized fasting blood glucose and lowered HOMA-IR from approximately 10–12 to around 3 in a diet-induced zebrafish Type 2 diabetes model, with clear dose-dependent improvements in oral glucose tolerance and fasting insulin levels.
2. Mechanistic Insights
The data reinforce Telomir-Zn’s mechanism of modulating intracellular metal homeostasis—particularly zinc and iron balance—to reduce oxidative stress, improve mitochondrial function and restore insulin receptor signaling pathways critical to glucose metabolism.
3. Clinical Development Implications
These preclinical results strengthen the scientific rationale for Telomir-Zn and align with the company’s FDA-cleared IND for a Phase 1/2 trial in triple-negative breast cancer, highlighting the broader therapeutic potential of its metal-homeostasis platform across metabolic and oncology indications.
